With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
This article was originally published in The Pink Sheet Daily
Executive Summary
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
You may also be interested in...
Atlas-Backed Firm Will Seek Pan-Ataxia Therapy With Biogen’s Assistance
Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
The Longest Round: NovImmune’s Eight-Year Series B
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.